Claims:

1. ~~A~~Use of a composition ~~for treating rheumatoid arthritis, which comprises~~ comprising (i) a chondrocyte; and (ii) a cell into which a gene encoding TGF-β (transforming growth factor-beta) is introduced in the preparation of a medicament for treating rheumatoid arthritis, wherein the cell in (ii) is hChonJb#7.

2. The ~~composition~~ use according to claim 1, wherein a ratio of (i) a chondrocyte; and (ii) the cell into which the gene encoding TGF-β (transforming growth factor-beta) is introduced ranges from 1:1 to 100:1.

3. The ~~composition~~ use according to claim 2, wherein the ratio of (i) the chondrocyte; and (ii) the cell into which the gene encoding TGF-β (transforming growth factor-beta) is introduced ranges from 1:1 to 3:1.

~~4. A use of a composition comprising (i) a chondrocyte; and (ii) a cell into which a gene encoding TGF-β is introduced in the preparation of a medicament for treating an inflammatory disease induced by a hyperimmune response, wherein the cell in (ii) is hChonJb#7.~~

~~5~~4. Use of a composition comprising (i) a chondrocyte; and (ii) a cell into which a gene encoding TGF-β is introduced in the preparation of a medicament for treating rheumatoid arthritis by inhibiting the expression or activity of a cytokine selected from the group consisting of IFN-γ, IL-6, IL-17A, IL-1β, and TNF-α, wherein the cell in (ii) is hChonJb#7.